NCT07478991 2026-03-18
VENP-A-QUI
PETHEMA Foundation
Phase 3 Not yet recruiting
Clinical Trials
124 trialsNCT04628026 2026-03-16
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT07469046 2026-03-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
NCT07463651 2026-03-11
TROPHY-15
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
NCT01366612 2026-03-09
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT07132684 2026-03-02
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT07407140 2026-03-02
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT03480360 2026-02-19
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Phase 3 Active not recruiting
NCT07407660 2026-02-12
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital
Phase 3 Not yet recruiting
NCT03594149 2026-01-02
AZABAC
Centre Henri Becquerel
Phase 3 Completed
NCT07232134 2025-11-20
AML-DS-2025
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT07223814 2025-11-03
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Not yet recruiting
NCT07075016 2025-08-19
EVOLVE 1
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06990321 2025-08-08
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
The First Hospital of Jilin University
Phase 3 Recruiting
NCT03897127 2025-07-17
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
University of Ulm
Phase 3 Active not recruiting
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT03507842 2025-03-17
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Asan Medical Center
Phase 3 Enrolling by invitation
NCT04314219 2025-03-13
PTCy-PMAT
King Faisal Specialist Hospital & Research Center
Phase 3 Recruiting
NCT05991908 2025-02-18
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT06829472 2025-02-17
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT05674539 2025-02-10
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Enrolling by invitation
NCT06810791 2025-02-06
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Nanfang Hospital, Southern Medical University
Phase 3 Recruiting
NCT04168502 2024-11-08
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Recruiting
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT03839771 2024-10-02
HOVON150AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Active not recruiting
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT02323022 2024-07-30
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 3 Completed
NCT06297772 2024-06-04
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital
Phase 3 Not yet recruiting
NCT04173533 2024-05-14
AMADEUS
University of Birmingham
Phase 3 Active not recruiting
NCT06345365 2024-04-10
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Zhongnan Hospital
Phase 3 Recruiting
NCT02013648 2024-02-23
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)
University of Ulm
Phase 3 Completed
NCT01497002 2024-01-31
AML2004
University of Leipzig
Phase 3 Completed
NCT02461537 2024-01-19
ETAL3-ASAP
DKMS gemeinnützige GmbH
Phase 3 Completed
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT02140242 2023-09-15
DaunoDouble
Technische Universität Dresden
Phase 3 Completed
NCT03719534 2023-06-27
Haplo HCT vs Haplo-cord HCT for Patients With AML
The First Affiliated Hospital of Soochow University
Phase 3 Completed
NCT05188326 2023-06-08
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
Associazione Qol-one
Phase 3 Completed
NCT05264883 2023-05-30
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT03846362 2023-03-16
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Unknown
NCT01191957 2023-03-10
GITMO-AMLR2
Gruppo Italiano Trapianto di Midollo Osseo
Phase 3 Completed
NCT04326764 2023-02-16
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
Phase 3 Terminated
NCT00406393 2023-01-04
BMT CTN 0402
Medical College of Wisconsin
Phase 3 Completed
NCT01339910 2023-01-04
BMT CTN 0901
Medical College of Wisconsin
Phase 3 Terminated
NCT05654194 2022-12-16
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT05457361 2022-07-14
VAH Versus VA for Salvage Therapy of R/R-AML
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT04676243 2022-05-25
Q-SOC
University Hospital Heidelberg
Phase 3 Withdrawn
NCT05382390 2022-05-19
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Phase 3 Unknown
NCT02927938 2022-04-21
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 3 Terminated
NCT02566395 2022-04-07
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health
Phase 3 Completed
NCT04490707 2022-03-24
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Zhongda Hospital
Phase 3 Unknown